Gilead Sciences reported $23.82B in Loan Capital for its fiscal quarter ending in September of 2026.





Loan Capital Change Date
AbbVie USD 62.48B 2.05B Jun/2026
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
ALKERMES USD 1.47B 5.38M Sep/2026
Alnylam Pharmaceuticals USD 2.11B 358.58M Sep/2026
Amgen USD 51.61B 250M Sep/2026
Biogen USD 7.29B 1.7M Sep/2026
BioMarin Pharmaceutical USD 3.51B 12.96M Sep/2026
Bristol-Myers Squibb USD 41.85B 244M Sep/2026
Coherus Biosciences USD 51.08M 496K Dec/2025
Eli Lilly USD 46.99B 872M Sep/2026
Gilead Sciences USD 23.82B 17M Sep/2026
GlaxoSmithKline GBP 21.7B 7.75B Sep/2026
Glaxosmithkline GBP 28.79B 10.26B Sep/2026
Incyte USD 28.42M 994K Jun/2026
J&J USD 35.8B 1.55B Sep/2026
Merck USD 49.69B 1.39B Sep/2026
Moderna USD 3.55B 2.95B Sep/2026
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Novartis USD 38.38B 893M Sep/2026
Pfizer USD 60B 498M Sep/2026
PTC Therapeutics USD 536.27M 749K Sep/2026
Puma Biotechnology USD 10.87M 222K Jun/2025
Regeneron Pharmaceuticals USD 1.99B 400K Sep/2026
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 16.28B 1.63B Sep/2026
Sarepta Therapeutics USD 699.39M 148.23M Sep/2026
United Therapeutics USD 100M 100M Jun/2024
Vertex Pharmaceuticals USD 3.5B 3.39B Sep/2026